

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM S-8

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
NURIX THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)**

Delaware
(State or Other Jurisdiction of
Incorporation or Organization)

27-0838048
(I.R.S. Employer
Identification No.)

**1700 Owens Street, Suite 205
San Francisco, California 94158**
(Address of Principal Executive Offices) (Zip Code)

**2020 Equity Incentive Plan
2020 Employee Stock Purchase Plan**
(Full Title of the Plans)

**Arthur T. Sands
President and Chief Executive Officer
Nurix Therapeutics, Inc.
1700 Owens Street, Suite 205
San Francisco, California 94158**
(Name and Address of Agent for Service)
(415) 660-5320
(Telephone Number, including area code, of agent for service)

Please send copies of all communications to:

**Michael A. Brown, Esq.
Amanda L. Rose, Esq.
Jennifer J. Hitchcock, Esq.
Fenwick & West LLP
555 California Street, 12th Floor
San Francisco, California 94104
(415) 875-2300**

**Christine Ring, Esq.
Chief Legal Officer and Secretary
Nurix Therapeutics, Inc.
1700 Owens Street, Suite 205
San Francisco, California 94158
(415) 660-5320**

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

**REGISTRATION OF ADDITIONAL SHARES
PURSUANT TO GENERAL INSTRUCTION E**

Nurix Therapeutics, Inc. (the “*Registrant*”) is filing this Registration Statement with the Securities and Exchange Commission (the “*Commission*”) to register (a) 1,948,742 additional shares of the Registrant’s common stock available for issuance under the Registrant’s 2020 Equity Incentive Plan (the “*2020 EIP*”) pursuant to the provision of the 2020 EIP providing for an annual 4% automatic increase in the number of shares reserved for issuance under the 2020 EIP and (b) 487,185 additional shares of the Registrant’s common stock available for issuance under the Registrant’s 2020 Employee Stock Purchase Plan (the “*2020 ESPP*”) pursuant to the provision of the 2020 ESPP providing for an annual 1% automatic increase in the number of shares reserved for issuance under the 2020 ESPP.

In accordance with General Instruction E of Form S-8, and only with respect to the common stock issuable under the 2020 EIP and 2020 ESPP, this Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statements on Form S-8 filed with the Commission on [July 24, 2020](#) (Registration No. 333-240065), [February 16, 2021](#) (Registration No. 333-253159), [January 28, 2022](#) (Registration No. 333-262406), and [February 9, 2023](#) (Registration No. 333-269671) to the extent not superseded hereby.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “*Exchange Act*”) are incorporated herein by reference:

- (a) the Registrant’s Annual Report on Form 10-K for the year ended November 30, 2023, filed with the Commission on February 15, 2024, pursuant to Section 13 of the Exchange Act;
- (b) all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report on [Form 10-K](#) referred to in (a) above; and
- (c) the description of the Registrant’s common stock contained in the Registrant’s registration statement on [Form 8-A](#) (File No. 001-39398) filed on July 20, 2020, under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

All documents and definitive proxy or information statements filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission. Unless expressly incorporated into this Registration Statement, a report deemed to be furnished but not filed on Form 8-K prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

Item 8. Exhibits.

Exhibit Number	Exhibit Description	Incorporated by Reference				Filed Herewith
		Form	File No.	Exhibit	Filing Date	
4.1	Restated Certificate of Incorporation of the Registrant	10-Q	001-39398	3.1	10/14/2020	
4.2	Amended and Restated Bylaws of the Registrant	8-K	001-39398	3.1	12/16/2022	
4.3	Form of Registrant’s Common Stock Certificate	S-1	333-239651	4.1	07/02/2020	
5.1	Opinion and Consent of Fenwick & West LLP					X
23.1	Consent of independent registered public accounting firm					X
23.2	Consent of Fenwick & West LLP (contained in Exhibit 5.1)					X
24.1	Power of Attorney (included on signature page of this Registration Statement)					X
99.1	2020 Equity Incentive Plan	S-1/A	333-239651	10.3	07/20/2020	
99.2	2020 Employee Stock Purchase Plan	S-1/A	333-239651	10.4	07/20/2020	
107.1	Filing Fee Table					X

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in San Francisco, California, on this 15th day of February, 2024.

NURIX THERAPEUTICS, INC.

/s/ Arthur T. Sands

Arthur T. Sands, M.D., Ph.D.
President and Chief Executive
Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Arthur T. Sands and Hans van Houte, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

Signature	Title	Date
<u>/s/ Arthur T. Sands</u> Arthur T. Sands, M.D., Ph.D.	President, Chief Executive Officer and Director <i>(Principal Executive Officer)</i>	February 15, 2024
<u>/s/ Hans van Houte</u> Hans van Houte	Chief Financial Officer <i>(Principal Accounting Officer and Principal Financial Officer)</i>	February 15, 2024
<u>/s/ David Lacey</u> David Lacey, M.D.	Chairman and Director	February 15, 2024
<u>/s/ Julia P. Gregory</u> Julia P. Gregory	Director	February 15, 2024
<u>/s/ Lori A. Kunkel</u> Lori A. Kunkel, M.D.	Director	February 15, 2024
<u>/s/ Judith A. Reinsdorf</u> Judith A. Reinsdorf, J.D.	Director	February 15, 2024
<u>/s/ Edward C. Saltzman</u> Edward C. Saltzman	Director	February 15, 2024
<u>/s/ Paul M. Silva</u> Paul M. Silva	Director	February 15, 2024

Calculation of Filing Fee Tables

FORM S-8
(Form Type)

NURIX THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

Security Type	Security Class Title	Fee Calculation Rule	Amount Registered (1)	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
Equity	Common Stock, \$0.001 par value per share	Rule 457(c) and Rule 457(h)	1,948,742 (2)	\$8.40 (3)	\$16,359,690 (3)	\$0.0001476	\$2,415
Equity	Common Stock, \$0.001 par value per share	Rule 457(c) and Rule 457(h)	487,185 (4)	\$7.14 (5)	\$3,478,501 (5)	\$0.0001476	\$514
Total Offering Amounts					\$19,838,191	—	\$2,929
Total Fee Offsets							—
Net Fee Due							\$2,929

- (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “*Securities Act*”), this Registration Statement shall also cover any additional shares of common stock of Nurix Therapeutics, Inc. (the “*Registrant*”) that become issuable in respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected without the Registrant’s receipt of consideration which results in an increase in the number of the outstanding shares of the Registrant’s common stock.
- (2) Represents 1,948,742 additional shares of the Registrant’s common stock to be reserved for issuance under the 2020 Equity Incentive Plan (“*2020 EIP*”) pursuant to the provision of the 2020 EIP providing for an annual automatic increase in the number of shares reserved for issuance under the 2020 EIP.
- (3) Estimated pursuant to Rules 457(c) and (h) of the Securities Act, solely for the purpose of calculating the registration fee for the additional shares to be reserved under the 2020 EIP, on the basis of the average of the high and low prices of the Registrant’s common stock as reported on the Nasdaq Global Market (“*Nasdaq*”) on February 8, 2024.
- (4) Represents 487,185 additional shares of the Registrant’s common stock available for issuance under the Registrant’s 2020 Employee Stock Purchase Plan (the “*2020 ESPP*”) pursuant to the provision of the 2020 ESPP providing for an annual automatic increase in the number of shares reserved for issuance under the 2020 ESPP.
- (5) Estimated pursuant to Rules 457(c) and (h) of the Securities Act, solely for the purpose of calculating the registration fee for the additional shares to be reserved under the 2020 ESPP, on the basis of the average of the high and low prices of the Registrant’s common stock as reported on Nasdaq on February 8, 2024. Under the 2020 ESPP, the purchase price of a share of common stock is equal to 85% of the fair market value of the Registrant’s common stock on the offering date or the purchase date, whichever is less.
- (6) The Registrant does not have any fee offsets.



555 California Street
12th Floor
San Francisco, CA 94104

415.875.2300
Fenwick.com

February 15, 2024

Nurix Therapeutics, Inc.
1700 Owens Street, Suite 205
San Francisco, California 94158

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

At your request, as your counsel, we have examined the Registration Statement on Form S-8 (the "**Registration Statement**") to be filed by Nurix Therapeutics, Inc., a Delaware corporation (the "**Company**") with the Securities and Exchange Commission (the "**Commission**") on or about February 15, 2024 in connection with the registration under the Securities Act of 1933, as amended (the "**Securities Act**"), of the issuance of an aggregate of 2,435,927 shares (the "**Shares**") of the Company's common stock, \$0.001 par value per share ("**Common Stock**"), consisting of (a) 1,948,742 additional Shares that are available for issuance by the Company upon the exercise or settlement of awards (including awards of stock options, restricted stock, stock bonuses, stock appreciation rights, restricted stock units and/or performance shares) granted or to be granted under the Company's 2020 Equity Incentive Plan (the "**2020 EIP**") pursuant to the provision of the 2020 EIP providing for an annual 4% automatic increase in the number of shares reserved for issuance under the 2020 EIP and (b) 487,185 additional Shares that are subject to issuance by the Company pursuant to purchase rights to acquire shares of Common Stock granted or to be granted under the Company's 2020 Employee Stock Purchase Plan (the "**2020 ESPP**") pursuant to the provision of the 2020 ESPP providing for an annual 1% automatic increase in the number of shares reserved for issuance under the 2020 ESPP. The 2020 EIP and the 2020 ESPP are each individually referred to herein as a "**Plan**" and collectively referred to in this letter as the "**Plans**."

As to matters of fact relevant to the opinions rendered herein, we have examined such documents, certificates and other instruments which we have deemed necessary or advisable, including a certificate addressed to us and dated the date hereof executed by the Company (the "**Opinion Certificate**"). We have not undertaken any independent investigation to verify the accuracy of any such information, representations or warranties or to determine the existence or absence of any fact, and no inference as to our knowledge of the existence or absence of any fact should be drawn from our representation of the Company or the rendering of the opinion set forth below. We have not considered parol evidence in connection with any of the agreements or instruments reviewed by us in connection with this letter.

In our examination of documents for purposes of this letter, we have assumed, and express no opinion as to, the genuineness and authenticity of all signatures on original documents, the authenticity and completeness of all documents submitted to us as originals, that each document is what it purports to be, the conformity to originals of all documents submitted to us as copies or facsimile copies, the absence of any termination, modification or waiver of or amendment to any document reviewed by us (other than as has been disclosed to us), the legal competence or capacity of all persons or entities (other than the Company) executing the same and (other than the Company) the due authorization, execution and

delivery of all documents by each party thereto. We have also assumed the conformity of the documents filed with the Commission via the Electronic Data Gathering, Analysis and Retrieval System (“**EDGAR**”), except for required EDGAR formatting changes, to physical copies submitted for our examination.

The opinions in this letter are limited to the existing General Corporation Law of the State of Delaware now in effect. We express no opinion with respect to any other laws.

Based upon, and subject to, the foregoing, it is our opinion that the Shares, when issued and sold by the Company in accordance with the terms (including, without limitation, payment and authorization provisions) of the applicable Plan and the applicable form of award agreement thereunder, against the Company’s receipt of payment therefor (in an amount and type of consideration not less than the par value per Share), and duly registered on the books of the transfer agent and registrar for the Shares in the name or on behalf of the holders thereof, will be validly issued, fully paid and non-assessable.

We consent to the use of this opinion as an exhibit to the Registration Statement and further consent to all references to us, if any, in the Registration Statement, the prospectuses constituting a part thereof and any amendments thereto. We do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder. This opinion is intended solely for your use in connection with the issuance and sale of the Shares subject to the Registration Statement and is not to be relied upon for any other purpose. In providing this letter, we are opining only as to the specific legal issues expressly set forth above, and no opinion shall be inferred as to any other matter or matters. This opinion is rendered on, and speaks only as of, the date of this letter first written above, and does not address any potential change in facts or law that may occur after the date of this opinion letter. We assume no obligation to advise you of any fact, circumstance, event or change in the law or the facts that may hereafter be brought to our attention, whether or not such occurrence would affect or modify any of the opinions expressed herein.

Very truly yours,

/s/ Fenwick & West LLP

FENWICK & WEST LLP

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Nurix Therapeutics, Inc. of our report dated February 15, 2024 relating to the financial statements, which appears in Nurix Therapeutics, Inc.'s Annual Report on Form 10-K for the year ended November 30, 2023.

/s/ PricewaterhouseCoopers LLP

San Jose, California
February 15, 2024